CORONA Remedies Limited has informed the Exchange regarding a press release dated March 30, 2026, titled CORONA Remedies announces strategic acquisition of Wokadine® in India .
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.3 pts less than Nifty Microcap 250 and 5.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
CORONA Remedies Limited has announced the acquisition of Wokadine®, a povidone-iodine brand, from Dr. Reddy's Laboratories, effective March 30, 2026. Wokadine® is ranked #2 in the Indian Povidone Iodine market, which is valued at INR 648 Cr (as per Pharmatrac MAT Feb'26). The brand has 46 years of legacy, comprises 14 SKUs, and is used by surgeons, ENT specialists, general physicians and gynaecologists. This marks CORONA Remedies' fifth acquisition and is described as a strategic fit with its existing core therapeutic areas. The deal will be fully funded through internal accruals and cash, with no debt being raised.
The acquisition expands CORONA's product portfolio and gives it entry into the INR 648 Cr Povidone Iodine segment. Being fully cash-funded and complementary to existing business, it is likely to be viewed positively by shareholders as a value-accretive move, though the deal size and financial impact have not been disclosed.